Lazard Asset Management
MRNA icon

Lazard Asset Management’s Moderna MRNA Stock Holding History

Lazard Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$577K Buy
+11,364
New +$530K ﹤0.01% 1332
2025
Q1 		– Sell
-2,669
Closed -$110K – 2471
2024
Q4 		$110K Sell
2,669
-11,516
-81% -$550K ﹤0.01% 1780
2024
Q3 		$947K Sell
14,185
-36,937
-72% -$3.39M ﹤0.01% 1099
2024
Q2 		$6.07M Buy
51,122
+40,951
+403% +$5.18M 0.01% 634
2024
Q1 		$1.08M Buy
10,171
+4,563
+81% +$460K ﹤0.01% 912
2023
Q4 		$556K Sell
5,608
-2,409
-30% -$203K ﹤0.01% 1083
2023
Q3 		$827K Buy
8,017
+1,078
+16% +$120K ﹤0.01% 1019
2023
Q2 		$842K Sell
6,939
-9,654
-58% -$1.29M ﹤0.01% 1023
2023
Q1 		$2.55M Buy
16,593
+510
+3% +$84.1K ﹤0.01% 871
2022
Q4 		$2.89M Sell
16,083
-43,824
-73% -$7.17M ﹤0.01% 834
2022
Q3 		$7.08M Buy
59,907
+19,799
+49% +$3M 0.01% 638
2022
Q2 		$5.73M Buy
40,108
+23,274
+138% +$3.33M 0.01% 709
2022
Q1 		$2.9M Sell
16,834
-29,655
-64% -$4.99M ﹤0.01% 838
2021
Q4 		$11.8M Sell
46,489
-43,500
-48% -$12.7M 0.01% 593
2021
Q3 		$34.6M Buy
89,989
+506
+0.6% +$187K 0.04% 357
2021
Q2 		$21M Buy
89,483
+69,859
+356% +$12.5M 0.02% 456
2021
Q1 		$2.57M Buy
19,624
+16,995
+646% +$2.46M ﹤0.01% 757
2020
Q4 		$274K Buy
+2,629
New +$266K ﹤0.01% 1058

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management's MRNA Position: Q1 2026 in Review

Lazard Asset Management opened a new position in Moderna (MRNA) in Q1 2026: 11,364 shares worth $577K. The stake represents ﹤0.01% of the portfolio and ranks #1332 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in MRNA as recently as Q4 2024.

Lazard Asset Management first reported a position in MRNA in Q4 2020 and has held it in 18 quarters since. The position peaked at $34.6M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Lazard Asset Management held 11,364 shares of Moderna worth $577K as of Q1 2026.
  • Moderna was a new Lazard Asset Management position in Q1 2026.
  • Moderna made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1332 holding.
  • Lazard Asset Management first reported a position in Moderna in Q4 2020 and has held it in 18 quarters since.
  • Lazard Asset Management's Moderna position peaked at $34.6M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.